MorphoSys and WACKER Expand Cooperation to Use WACKER's ESETEC® Technology
News Feb 04, 2010
MorphoSys AG and Wacker Chemie AG announced an expansion of their existing cooperation in the use of WACKER's bacterial secretion technology ESETEC®.
As a result, MorphoSys will now be able to use the WACKER technology for the production of antigen material in addition to the production of antibodies in both the early development phase of therapeutic projects as well as in the production of diagnostic and research antibodies.
The technology complements MorphoSys's existing production platforms. It could offer significant advantages with regard to the production of novel antigens, which have proven difficult to produce with conventional expression systems.
"The use of WACKER's secretion technology for antigen production allows us to approach development programs where the production of the disease-relevant target molecule represents a major challenge. This could offer us and our partners a head-start in therapeutic projects against novel drug targets including bacterial antigens in current and future infectious disease programs", explained Dr. Marlies Sproll, Chief Scientific Officer at MorphoSys AG.
In October 2009, MorphoSys signed a first alliance focused on the discovery and development of therapeutic antibodies for hospital-acquired infections with Daiichi Sankyo.
"The extension of our existing collaboration with MorphoSys underpins the success of our protein production technology ESETEC®" said Dr. Thomas Maier, Managing Director at Wacker Biotech GmbH, Wacker Chemie AG's subsidiary for custom manufacturing of biopharmaceuticals.
"Since we introduced this innovation to the biopharmaceutical market we see that more and more companies revisit E. coli as production host to benefit from shorter development timelines", he added.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019